Use the complete Bispecific antibody clinical trial and drug landscape to your advantage
What we cover
This database solution is manually curated by sector-specific scientists and includes clinical trial and drug records for preclinical, active, approved, and discontinued antibody-based drugs that are designed to bind to two or more target antigens. We also cover:
- Whole Antibodies
- Antibody Fragments
- Augmented Antibodies
- Bispecific Fusion Proteins
How Beacon helps
Here are a few example use cases that have benefitted our clients in accelerating their Bispecific development programs:
- Benchmark drug development and clinical trial strategies against competitors.
- Getting an in-depth competitive landscape overview of the competitors and their assets in the clinic.
- Drastically reduce manual research time with our database solution which allows users to rapidly assemble data for analysis on phase distribution, targets, disease indication, drug discontinuations and much more.
- Identify new players and new assets entering the clinic and monitor their progress.
How Beacon Bispecific works
Search the clinical trial and drug landscape by multiple targets, scaffold and over 80 different bispecific formats, instantaneously and/or extract the data points you need to conduct more complex analysis.
How we source the data for Bispecific/Multispecific Therapies
We house all publicly available sources of data updated with 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
The 2022 Bispecific Landscape Review
Bispecific: SITC Pre-Conference Planner 2022
Bispecific: ESMO Post-Conference Report 2022
What our customers say
"I’ve rarely seen such dedication from a service provider in understanding and responding to our needs"
Competitive Intelligence Manager
Bispecific Drug Developer
Our Bispecific Expert
Shailee Patel is the lead research analyst for bispecific-related drugs and trials in the Beacon Targeted Therapies team.
Sign up to her weekly newsletter with the latest bispecific landscape insights and updates with data from Beacon Bispecific.
Other Beacon Solutions
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Covering all engineered and non-engineered immune cell therapies, including CAR-T, TCR, NK, TILs, Gamma-Delta T Cells and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Covering all pharmaceutical grade microbiome-based therapeutics across all disease indications – Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
Any questions? Contact us
To learn more about how we can tailor Beacon Bispecific to help you, get in touch with our sales team
Bispecific Account Manager
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.